Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-1701 in Locally Advanced/Metastatic HER2 Expressing Solid Tumors
NCT04257110Phase 1Completed
- Sponsor
- Bliss Biopharmaceutical
- Start
- Jul 2020
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of BB-1701 in breast cancer, gastric cancer (GC), gastroesophageal junction cancer and 3 more (5 arms), sponsored by Bliss Biopharmaceutical. Primary endpoints: Number of subjects with adverse events and serious adverse events up to 2 years, Number of subjects with dose limiting toxicity and 1 more. Started Jul 2020; status: completed.
02
Drugs
BB-1701
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction cancersolid tumorbladder cancer
Beyond the preview
Go deeper on NCT04257110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04257110.